Market cap
₹31,850 Cr
Recently Viewed
Clear AllNSE: EMCURE | BSE: 544210
₹1,680.10
₹-49.80
(-2.88%)
As on 30-Apr-2026IST
Market cap
₹31,850 Cr
Revenue (TTM)
₹8,850 Cr
P/E Ratio
36.6
P/B Ratio
6.4
Div. Yield
0.2 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹870 Cr
ROE
19.2 %
ROCE
22.5 %
Industry P/E
37.77
EV/EBITDA
18.2
Debt to Equity
0.2
Book Value
₹262.4
EPS
₹47.9
Face value
10
Shares outstanding
189,589,547
CFO
₹6,491.08 Cr
EBITDA
₹10,649.27 Cr
Net Profit
₹4,222.35 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Emcure Pharmaceuticals
| 23.1 | 1.7 | 17.0 | 66.5 | -- | -- | -- |
|
BSE Healthcare
| 2.7 | 6.8 | 7.9 | 5.7 | 24.7 | 13.8 | 11.1 |
|
Company
|
2025
|
|---|---|
|
Emcure Pharmaceuticals
| -6.6 |
|
BSE Small Cap
| -6.6 |
|
BSE Healthcare
| -3.3 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Emcure Pharmaceuticals
|
1,680.1 | 31,850.1 | 8,850.1 | 894.8 | 15.2 | 19.8 | 36.6 | 6.4 |
| 376.3 | 3,423.1 | 2,521.8 | 202.5 | 9.6 | 14.3 | 16.9 | 2.3 | |
| 1,038.2 | 12,733.9 | 2,512.3 | 543.7 | 28.3 | 19.3 | 23.4 | 4.0 | |
| 444.6 | 7,694.1 | 1,053.1 | 293.6 | 32.3 | 24.6 | 26.2 | 5.9 | |
| 1,142.0 | 11,927.8 | 1,158.7 | 309.6 | 31.9 | 17.3 | 38.2 | 6.3 | |
| 363.6 | 3,963.6 | 159.3 | 47.8 | 39.0 | 18.6 | 82.9 | 14.3 | |
| 15,003.0 | 19,243.2 | 1,575.1 | 179.1 | 14.9 | 11.4 | 107.4 | 11.6 | |
| 2,295.0 | 3,799.8 | 707.5 | 115.2 | 17.8 | 19.4 | 33 | -- | |
| 899.2 | 4,138.8 | 588.5 | 102.9 | 22.1 | 12.7 | 40.7 | 4.9 | |
| 211.9 | 5,585.6 | 7.1 | -274.7 | -4,008.3 | -140.4 | -- | 8.4 |
5 min read•By Hemkesh Khattar
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology,... respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the development and commercialization of Poviztra, a semaglutide injection for weight loss. Emcure Pharmaceuticals Limited was incorporated in 1981 and is based in Pune, India. Read more
Incorporated
1981
Chairman
Berjis Desai
Managing Director
Satish Mehta
Headquarters
Pune, Maharashtra
Website
Looking for more details about Emcure Pharmaceuticals Ltd’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Emcure Pharmaceuticals Ltd is ₹1,680.10 (NSE) and ₹1,679.95 (BSE) as of 30-Apr-2026 IST. Emcure Pharmaceuticals Ltd has given a return of 66.49% in the last 1 years.
The P/E ratio of Emcure Pharmaceuticals Ltd is 36.61 times as on 30-Apr-2026, a 3 discount to its peers’ median range of 37.77 times.
The P/B ratio of Emcure Pharmaceuticals Ltd is 6.40 times as on 30-Apr-2026, a 164 premium to its peers’ median range of 2.42 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
29.84
|
4.58
|
|
2024
|
0.00
|
0.00
|
|
2023
|
0.00
|
0.00
|
|
2022
|
0.00
|
0.00
|
|
2021
|
0.00
|
0.00
|
The 52-week high and low of Emcure Pharmaceuticals Ltd are Rs 1,769.00 and Rs 983.00 as of 30-Apr-2026.
Emcure Pharmaceuticals Ltd has a market capitalisation of ₹ 31,850 Cr as on 30-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Emcure Pharmaceuticals Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.